Shares of NeoGenomics surged 11.1% to $14.89 in pre-market trading on July 29, after the oncology diagnostics company posted second-quarter results that handily topped Wall Street expectations and raised its outlook for the rest of the year. With shares now trading within a 52-week range of $4.72 to $15.57 , the stock is approaching the top of its range — forcing investors to decide whether this is a breakout or a ceiling.

  • The Earnings Surprise That Actually Mattered Was Profit, Not Revenue

Revenue hit $201.7 million, up 11% year-over-year, beating the $199 million analyst consensus by just 1.4% — a modest top-line beat at best. The real story was earnings: non-GAAP EPS of $0.05 crushed the $0.033 estimate by 51%, driven by higher-margin tests and tighter cost controls. For a company that was losing money as recently as Q1, flipping to profitability is a meaningful signal that scale is finally working in its favor.

  • Higher-Value Cancer Tests Are Quietly Rewriting the Business Model

Clinical revenue grew 14%, powered by a 12% jump in the average price NeoGenomics gets paid per test and a 2% bump in test volumes.

Revenue from advanced gene-sequencing tests — which analyze tumor DNA to guide treatment decisions — soared 26%. The takeaway: NeoGenomics is selling more expensive, more complex tests, not just more tests. Adjusted gross margins expanded by 260 basis points (or 2.6 percentage points) year-over-year , showing the mix shift is dropping to the bottom line.

  • Raised Guidance Signals Confidence, With a Caveat

Management lifted its full-year revenue forecast to $802–$806 million and bumped adjusted EBITDA guidance to $56–$58 million, up from $55–$57 million.

However, the $804 million midpoint still sits roughly 0.5% below analyst consensus of $808 million , suggesting management is hedging — especially since the pharma services business remains weak, with reduced segment guidance and a recovery not expected until 2027.

  • The Valuation Question Looming Over the Rally

At $14.89 and a $1.7 billion market cap, investors are paying roughly 30× the midpoint of 2026 EBITDA guidance for a company just crossing the profitability threshold. Leerink Partners has a $25 price target , implying significant upside — but that assumes the high-value testing trend sustains. The key risk: a high fixed-cost base could quickly erode margins if revenue momentum stalls. Today's pop is earned, but the stock's proximity to its 52-week high demands that execution stay flawless.